LY4152199 / Eli Lilly - LARVOL DELTA

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress) (ASH 2025) - P1 | "Blood. 2024,144(1):4511-20"

Clinical • First-in-human • IO biomarker • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia

Sarah Cannon Research Institute to Present Research on Advances in Blood Cancers…at 2025 ASH Annual Meeting & Exposition (Sarah Cannon Research Institute (SCRI))

Clinical data • Acute Myelogenous Leukemia • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Myelodysplastic Syndrome • Waldenstrom Macroglobulinemia

LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies (ASH 2024) - "In co-culture assays with T cells and BAFF-R-expressing malignant B cells, LY4152199 engaged both CD3 and BAFF-R to induce concentration-dependent T-cell activation and T-cell mediated cytotoxicity, which was more potent than mosunetuzumab, a comparator CD20xCD3 bispecific antibody and a clinical benchmark for a TCE with lower cytokine release syndrome in B cell malignancies. Taken together, LY4152199 exhibits specificity, desirable functional activity and good developability. It has demonstrated the potential as a first-in-class BAFF-RxCD3 bispecific antibody to treat BAFF-R-positive B cell malignancies, including relapsed or refractory cases with CD19/CD20 expression loss."

B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • TNFRSF13C

A Study of LY4152199 in Participants With Previously Treated B-cell Cancers and Leukemia (clinicaltrials.gov) - P1 | N=295 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial • B Cell Lymphoma • Burkitt Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (PRNewswire) - "In an oral presentation, Lilly will report results from the Phase 3 BRUIN CLL-321 study, which is evaluating pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)....Additionally, Lilly will have poster presentations that share analyses of real-world data, including looking at overall survival associated with treatment sequences in patients with CLL/SLL, and pre-clinical data for a first-in-class B-cell activating factor receptor (BAFF)-RxCD3 bispecific antibody for the treatment of certain B-cell malignancies."

P3 data • Preclinical • Real-world • Chronic Lymphocytic Leukemia • Oncology • Small Lymphocytic Lymphoma